The concern of generic competition has repeatedly loomed above copyright’s blockbuster drug, Viagra, raising questions about the outlook of related pharmaceutical ventures. While first years saw significant profits, the intellectual property end has created the door for discounted substitutes, likely lowering profitability and posing a genuine ha